BioWorld MedTech

Jan. 12, 2015

InVivo reopens enrollment for Neuro-Spinal Scaffold

InVivo Therapeutics (Cambridge, Massachusetts) reported the reopening of subject enrollment for the company's ongoing pilot trial of its investigational Neuro-Spinal Scaffold in patients with acute spinal cord injury. Read More

It's Complicated: Genome studies broaden and deepen as methods progress

FDA grants CLIA waiver for molecular diagnostic test for influenza A & B

Inside the Beltway: Palmetto's Putcha: FDA oversight of LDTs could push testing to clinics

Attached to today's issue: The MDD 4Q Report.

Financings: PureTech closes on $50 million growth stage investment round

Report from Europe; Mauna Kea reports its sales are up 10% despite 'sharply contrasting trends'

HIT Bits: Mirth to power patient health information for Arizona network

MDD's Stock Market Winners and Losers

MDD's Stock Report for the week of 1/2-1/9

Briefly noted

People in Places

Product briefs

MDD's Neurology Extra

MDD's 4Q Report: Mergers and Acquisitions: Fewer, but more valuable, deals are the trend for last quarter of 2014

4Q14 Deals Chart

MDD's 4Q Report: Financings: Series A funding and IPOs show steady resolve in 4Q14

4Q14 Financial Chart

MDD's 4Q Report: Inside the Beltway FDA publishes revised draft guidance for LDT regulation

MDD's 4Q Report: Agreements/contracts: End of year slows down a bit, but still sees quality partnerships

Today's news in brief

BioWorld

BioWorld briefs for May 20, 2026.

News in brief

BioWorld Asia

BioWorld Asia briefs for May 19, 2026

WHO declares Ebola outbreak a public health emergency of international concern

BioWorld

The threat posed by the Ebola outbreak in the Democratic Republic of Congo has intensified, with the confirmation that it is caused by the Bundibugyo species of...

Acid alpha-glucosidase molecular structure isolated on black

‘Detargeted’ targeted gene therapy improves activity in Pompe

BioWorld

A new strategy aims to improve gene therapy for Pompe disease by optimizing both the genetic component that restores the function of a deficient lysosomal enzyme...

Nxera Pharma prepares and tests new GPR17 antagonists

BioWorld Science

Nxera Pharma UK Ltd. has identified new uracil nucleotide/cysteinyl leukotriene receptor (GPR17; P2Y-Like) antagonists potentially useful for the treatment of...